Biotech Precigen raises $75M to advance treatments for rare diseases
Precigen Inc. (NASDAQ: PGEN) has raised $75 million in a public offering that closed Friday and intends to use the proceeds to speed development of its experimental treatments for multiple rare diseases.
The clinical-stage biotech, which is developing gene and cell therapies for cancers, autoimmune disorders and infectious diseases, sold 42.86 million shares of common stock for $1.75 each. The company also gave the underwriters an option to buy up to 6.43 million additional shares in the 30 days …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
More News: Autoimmune Disease | Biotechnology | Cancer | Cancer & Oncology | Genetics | Health Management | Infectious Diseases | Pharmaceuticals | Rare Diseases